With a career path traversing clinical medicine, molecular genetics and systems biology, Dr. Tian is primarily interested in applying the powerful systems approach with the enabling genomics, single cell transcriptomics and proteomics technologies to address some of the most pressing issues pertaining to human health: cancer and stem cell biology, immunity, and disease biomarker discovery. He directs the interdisciplinary cancer and stem cell group at ISB striving to dissect the clonal origin of cancer heterogeneity, aiming to identify the tumor-initiating cells and the underlying genomic landscape and physical properties for defining their tumorigenic activities. Dr. Tian has led the development of gene signature panels for cancer patient stratification, and has elucidated protein interaction networks and relevant phosphorylation events in the Wnt signaling pathway for potential therapeutic targeting. He also contributed to the molecular characterization of multiple Th cell subsets (e.g. Th17, follicular T cells) through transcriptomic profiling and genome-wide mapping of protein-DNA interactions.Dr. Tian collegially reaches out to local and national medical research communities (UW-Medicine, Swedish Hospital, FHCRC, MD Anderson) to disseminate ISB strategy and technologies. His research has been supported by multiple NIH and DoD program/center projects, including a highly competitive R01 award addressing NCI’s provocative questions. Dr. Tian is on faculty of the UW-Instit
Cancer and stem cell biology, single cell analysis technology, hematopoiesis, immunology.